Amicus Therapeutics, a clinical-stage pharmaceutical company focused on therapeutics for diseases caused by misfolding proteins, announced the terms of its IPO on Thursday. The company plans to offer 5 million shares at a price between $14.00 and $16.00. Morgan Stanley and Merrill Lynch are the joint bookrunners on the deal.
